Laurus Labs Appoints Two Independent Directors, Invests in JV

• Board approved appointment of Dr. Shekhar Mande and Ms. Sutapa Banerjee as Independent Directors for five-year terms effective July 2, 2026.
• Approved additional investment of €9.8 million in joint venture KRKA Pharma to fund manufacturing facility capex.
• Approved voluntary closure of non-material German step-down subsidiary Laurus Generics GmbH with nil turnover.